Rynek i konsumenci · 14.11.1994

Proposed Rule: Requirements for Child-Resistant Packaging; Packages Containing 250 mg or More of Naproxen

Under the Poison Prevention Packaging Act of 1970, the Commission is proposing a rule to require child-resistant packaging for naproxen preparations containing 250 mg or more of naproxen per package. Naproxen is marketed as an anti-inflammatory drug. It is used to treat various forms of arthritis, mild to moderate pain, and menstrual pain. The Commission has preliminarily determined that child- resistant packaging is necessary to protect children under 5 years of age from serious personal injury and serious illness resulting from ingesting naproxen.